SCHEMBL5605854

SCHEMBL5605854

Cc1cc2c(F)c(Oc3ncnn4cc(OCCCC5CCCNC5)c(C)c34)ccc2[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.71
CYP3A4 P08684 12/20 0.71
KCNH2 Q12809 3/20 0.65
FGFR1 P11362 6/20 0.61
STK10 O94804 3/20 0.61
MAP4K4 O95819 3/20 0.61
RET P07949 3/20 0.61
PDGFRB P09619 3/20 0.61
DDR1 Q08345 3/20 0.61
SLK Q9H2G2 3/20 0.61
EPHB6 O15197 2/20 0.61
RIPK2 O43353 2/20 0.61
ABL1 P00519 2/20 0.61
EGFR P00533 2/20 0.61
LCK P06239 2/20 0.61
CSF1R P07333 2/20 0.61
HCK P08631 2/20 0.61
KIT P10721 2/20 0.61
SRC P12931 2/20 0.61
PDGFRA P16234 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9996546 0.91 KDR (0.77) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL1227490 0.87 KDR (0.84) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL1228157 0.83 KDR (0.75) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL3451491 0.82 KDR (0.78) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL1227526 0.82 KDR (0.78) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL14140810 0.82 KDR (0.77) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL1227548 0.82 KDR (0.77) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL1227649 0.81 KDR (0.76) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL1227552 0.81 KDR (0.77) KDRCYP3A4KCNH2FGFR1STK10
SCHEMBL12899428 0.81 KDR (0.79) KDRCYP3A4KCNH2FGFR1STK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265113-B2 Inhibitors of kinases BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-04 US disclosed
US-20050124621-A1 Novel inhibitors of kinases BHIDE RAJEEV S (US) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124621-A1 Novel inhibitors of kinases FGFR1, FLT1, FGFR2 KDR 7/4885CYP3A4 3014/4885KCNH2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.